Serial No. 09/674,815 5836-01-MJA (PC17416)

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

RECEIVED GENTRAL FAX CENTER

Claims 1-31 (cancelled)

SEP 2 8 2006

Claim 32 (withdrawn): The composition of Claim 25 wherein the 4-amino-3-substituted-butanoic acid derivative is pregabalin.

Claim 33 (cancelled)

Claim 34 (currently amended): A pharmaceutical composition comprising:

- (a) [[an]] a neutral α amino acid, and
- (b) a 4-amino-3-substituted-butanoic acid derivative selected from the group consisting of gabapentin and pregabalin, wherein the pharmaceutical composition is a solid.

Claim 35 (currently amended): The composition of Claim 34, wherein the neutral \$\alpha\$-amino acid is one or more selected from: glycine, phenylglycine, hydroxyphenylglycine, dihydroxyphenylglycine, L_alanine, hydroxy-L_alanine, L_leucine, hydroxy-L_leucine, dihydroxy-L_leucine, hydroxy-L_leucine, hydroxy-L_leucine, hydroxy-L_isoleucine, methylene-L-norleucine, L_ketonorleucine, L_isoleucine, hydroxy-L_isoleucine, L-valine, hydroxy-L_valine, L_isovaline, L_norvaline, hydroxy-L_isoleucine, L_valine, hydroxy-L_valine, L_isovaline, L_norvaline, hydroxy-L_isoleucine, hydroxy-L_ketonorvaline, L_methionine, L_homomethionine, L_ethionine, L_threonine, acetyl-L_threonine, L_tryptophan, hydroxy-L_tryptophan, methyl-L_tryptophan, L_tryosine, hydroxy-L_tryosine, methyl-L_tryosine, bromo-L_tryosine, dibromo-L_tryosine, L_levodopa, L_methyldopa, L_throxine, L_serine, acetyl-L_serine, L_homoserine, acetyl-L_homoserine, ethyl-L_homoserine, propyl-L_homoserine, butyl-L_homoserine, L_cystine, L_homocystine, methyl-L_cysteine, allyl-L_cysteine, propyl-L_cysteine, L_phenylalanine, dihydro-L_phenylalanine,

Serial No. 09/674,815 5836-01-MJA (PC17416)

hydroxymethyl-L-phenylalanine, L-aminobutyric acid, L-aminoisobutyric acid, L-aminobutyric acid, dichloro-L-aminobutyric acid, dihydroxy-L-aminobutyric acid, phenyl-L-aminobutyric acid, L-aminobutyric acid, L-aminobutyr

b, D-and DL-forms of noutral α-amino acids;
- alkali-salts, acid amides, alkyl-substituted derivatives of acid amides or alkyl-esters of the
L-; D- and DL-forms of acidio-α amino-acids;
- acid addition salts or monoacylated derivatives of the L., D. and DL forms of basic
α-amino acids;
— α,ω-diaminodicarboxylic acids; and
- acidic amino acid-basic amino acid adducts of the L., D- and DL forms of acidic a amino
acids and the L., D. and DL forms of basic or amino acids.

Claim 36 (currently amended): The composition of Claim [[34]] $\underline{35}$, wherein the <u>neutral</u> α -amino acid is one or more selected from:

glycine, phenylglycine, hydroxyphenylglycine, dihydroxyphenylglycine, L-alanine, hydroxy-L-alanine, L-leucine, hydroxy-L-leucine, dihydroxy-L-leucine, L-isoleucine, hydroxy-L-isoleucine, L-valine, hydroxy-L-valine, L-isovaline, and the D- and DL-forms thereof.

neutral & amino acids consisting of glycine, phonylglycine, hydroxyphonylglycine, dihydroxyphonylglycine, L alanine, hydroxy-L alanine, L-loucine, hydroxy-L leucine, dihydroxy-L leucine, hydroxy-L leucine, hydroxy-L isoleucine, hydroxy-L isoleucine, hydroxy-L valine, hydroxy-L valine, L isovaline, L norvaline, hydroxy-L norvaline, hydroxy-L ketonorvaline, L-methionine, L-homomethionine, L othionine, L threonine, acetyl L threonine, L tryptophan, hydroxy-L tryptophan, methyl-L tryptophan, L tyrosine, hydroxy-L tyrosine, mothyl-L tyrosine, bromo-L tyrosine, dibromo-L tyrosine, 3,5 diiodo-L tyrosine, acetyl-L tyrosine, chloro-L tyrosine, L m-tyrosine, L levodopa, L

methyldopa, L-thyroxine, L-serine, acetyl L-serine, L homoserine, acetyl-L-homoserine, ethyl-L-homoserine, propyl-L homoserine, butyl-L-homoserine, L-eystine, L homocystine, methyl-L-cysteine, propyl-L cysteine, L phenylalanine, dihydro-L phenylalanine, hydroxymethyl-L phenylalanine, L aminobutyric acid, L-aminoisebutyric acid, L-ketoaminobutyric acid, dichloro-L aminobutyric acid, dibydroxy-L aminobutyric acid, phenyl-L-aminobutyric acid, L aminovaleric acid, L-aminohydroxyvaleric acid, dihydroxy-L aminovaleric acid, L-aminohexanoic acid, methyl-L-aminohoxanoic acid, L-aminohexanoic acid, L-aminohexanoic acid, methyl-L-aminohoxanoic acid, L-aminohexanoic acid, L-aminohexanoic acid, L-aminohexanoic acid, methyl-L-aminohoxanoic acid, L-aminohexanoic acid, L-ami

acidic & amino-acids consisting of L-aspartic acid, L-glutamic acid, L-carbocysteine, L-aminoglutaric acid, L-aminosuccinic acid, L-aminoadipic acid, L-aminopimelic-acid, hydroxy-L-aminopimelic-acid, methyl-L-aspartic-acid, hydroxy-L-aspartic acid, methyl-hydroxy-L-glutamic-acid, methyl-hydroxy-L-glutamic-acid, L-methyleneglutamic-acid, hydroxy-L-glutamic-acid, dihydroxy-L-glutamic-acid and hydroxy-L-aminoadipic-acid and the D-and-DL-forms thereof;

basic a amine acids consisting of L-arginine, L-lysine, L-ornithine, L-canavanine, L-eanaline, hydroxy L-lysine, L-homoarginine, hydroxy L-bomoarginine, hydroxy L-ornithine, L-diaminopropionic acid, L-diaminohexancic acid, L-diaminobutyric acid, L-diaminovaleric-acid, L-diaminoheptanoic acid, and L-diaminocetanoic acid and the D-and DL-forms thereof; and

α,ω diaminodicarboxylic acids consisting of diaminosuccinic acid, diaminoglutaric acid, diaminoadipic acid and diaminopimelic acid;

provided that, when said α amino acid is an adipic α amino acid, it is used in the form of the corresponding alkali salt, acid amide, alkyl-substituted derivative of acid amide or alkyl-ester thereof, or when said α amino acid is a basic α amino acid, it is used in the form of the corresponding acid addition salt or monoacylated derivative thereof, or

said acidic α-amino acid and said basic α-amino acid are also used in the form of the corresponding acidic amino acid-basic amino acid adduct.

Claim 37 (currently amended): The composition of Claim 34, wherein a total amount of the neutral α-amino acid is in the range of 0.001 - 80 moles per mole of the 4-amino-3-substituted-butanoic acid derivative.

Serial No. 09/674,815 5836-01-MJA (PC17416)

Claim 38 (previously presented): The composition of Claim 34, wherein the 4-amino-3-substituted-butanoic acid derivative is gabapentin.

Claim 39 (cancelled)